Researchers from IDIBELL and ICO have participated in a multicenter study, published in Nature Genetics, which shows that the implantation of human tumors in nude mice does not lead to additional DNA changes.
Xenograft Animal Models Recapitulate Genetic Behavior of Original Human Tumors Read More »
Aptadel Therapeutics is a preclinical company co-founded by IDIBELL focused on developing a new platform for targeted therapy against cancer.
Aptadel, the new IDIBELL’s spinoff Read More »
The study lead by Columbia University, in collaboration with IDIBELL and ICO, analysed thousands of tumours. They found that the key genetic programs necessary for the survival of cancer cells are controlled by only 24 modules, each one comprising only a handful of Master Regulators proteins working in concert.
Cancer’s Key Vulnerabilities found by Big Data Analysis Read More »
